Background: TAR DNA-binding protein 43 (TDP-43) is one of the major disease proteins in frontotemporal lobar degeneration with ubiquitin immunoreactivity. Approximately one-fourth of subjects with pathologically confirmed Alzheimer disease (AD) have abnormal immunoreactivity. The aim of this study was to determine whether subjects with pathologically confirmed AD and abTDP-43 immunoreactivity have distinct clinical, neuropsychological, imaging, or pathologic features compared with subjects with AD without abTDP-43 immunoreactivity.
of the major disease proteins in neuronal and glial inclusions in FTLD-U. 2 The clinical syndrome most commonly associated with FTLD-U is behavioral variant frontotemporal dementia, characterized by behavioral and personality changes and executive dysfunction. 3 The average age at onset of subjects with FTLD-U is less than 65 years; however, age at onset can be as old as 89 years, 4 and MRI typically reveals a frontotemporal pattern of gray matter loss. 5 Recently it has been shown that approximately 25% of subjects with pathologically confirmed Alzheimer disease (AD) also have abnormal TDP-43 (abTDP-43) immunoreactivity 6 ; however, the significance of abTDP-43 immunoreactivity in AD is unknown. The abTDP-43 immunoreactivity in AD was confirmed as pathologic by immunohistochemistry and biochemistry. 6 Furthermore, whenever abTDP-43 immunoreactivity occurred in AD, there was a loss of the normal nuclear staining of TDP-43. 6 Our primary aim therefore was to determine whether subjects with pathologically confirmed AD and abTDP-43 immunoreactivity had distinct clinical, neuropsychological, imaging, or pathologic features compared with subjects who had AD without abTDP-43 immunoreactivity. The technique of voxelbased morphometry (VBM) was chosen to assess MRI patterns of volume loss across groups of AD subjects with and without abTDP-43 immunoreactivity because it is automated and can assess regional patterns of atrophy throughout the entire brain without requiring any a priori assumptions regarding which structures to assess.
Given a recently proposed classification scheme for FTLD-U that has been reported to correlate with clinical phenotype, 7 as a secondary aim, we also set out to classify cases with abTDP-43 immunoreactivity and to assess whether there were any clinical, neuropsychological, imaging, or pathologic differences among the different types.
METHODS Subject selection. The neuropathology database of the Alzheimer's Disease Research Center (ADRC) and Alzheimer's Disease Patient Registry (ADPR) were que-ried to identify all subjects with 1) AD-type pathologic changes that meet criteria for at least intermediateprobability AD 8 with Braak neurofibrillary tangle (NFT) Stage IV or greater, 9 2) neuropsychometric testing, and 3) a usable volumetric MRI scan. All subjects had been studied prospectively with yearly clinical evaluations, cognitive and neuropsychometric testing, and MRIs. The diagnosis of dementia was based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, 10 22 with modifications as previously described. 23 Pathologic methods. All subjects underwent standardized neuropathologic examination using the recommended diagnostic protocol for AD. 24 In each case, Braak NFT stage 9 and plaque score was determined. 24 Diagnosis of AD was made according to the National Institute on Aging and Reagan Institute Working Group (NIA-Reagan) criteria. 8 Additional pathology, including Lewy bodies (LBs), was recorded. The presence of hippocampal sclerosis (HpScl) was diagnosed if there were neuronal loss and gliosis in the subiculum and CA1 regions of the hippocampus that were disproportionate to the degree of neurofibrillary degeneration. 6 For each subject, a standardized section of medial temporal lobe that included hippocampus, parahippocampal gyrus, occipitotemporal gyrus, and inferior temporal gyrus was analyzed with TDP-43 immunohistochemistry (1:8,000; Pro-teinTech Group, Chicago, IL). Abnormal TDP-43 immunoreactivity was assessed and classified (D.W.D. and D.A.S.) based on the scheme proposed by Mackenzie et al. 7 Type 1 was characterized by moderate to numerous abTDP-43 immunoreactive neurites and neuronal cytoplasmic inclusions (NCIs) predominantly within layer II of the cortex and a variable density of granular cytoplasmic inclusions within granule cells of the dentate gyrus of the hippocampus. Some Type 1 cases also had neuronal intranuclear inclusions (NII). Type 2 was characterized by long neurites in middle and upper cortical layers with sparse or no NCIs and usually no NII. Dentate fascia inclusions were usually round Pick body-like inclusions. Type 3 was characterized by NCIs with sparse neurites again most numerous in upper cortical layers. The dentate gyrus in Type 3 had variable NCIs. Cases with abTDP-43 immunoreactivity that was sparse and sometimes associated with NFT and that did not fit into any of the above three types were classified as histologic Type 0.
Genetic analysis. All subjects with stored DNA and NII underwent genetic screening for mutations in all 13 exons in the progranulin gene, as previously described. 25 Subjects with NII were chosen for genetic screening because NII have been identified in all pathologically confirmed subjects with progranulin mutations. 26 Image analysis. All subjects had a T1-weighted volumetric MRI scan acquired at 1.5 tesla (22 ϫ 16.5-cm or 24 ϫ 18.5-cm field of view, 25°flip angle, 124 contiguous 1.6-mmthick coronal slices). If a subject had more than one MRI, the MRI closest to death was chosen to better correlate the neuroimaging findings with postmortem pathology. An optimized method of VBM, implemented using SPM2 (http:// www.fil.ion.ucl.ac.uk/spm), 27 was used to assess the patterns of gray matter atrophy in each group compared with a group of 84 living healthy controls who were age and sex matched to the study cohort. All controls were recruited through the ADRC/ADPR and have been previously defined. 28 The processing steps were performed as previously described. 28, 29 Briefly, all magnetic resonance scans were normalized to a customized template created from all subjects in the study. The spatial normalization was optimized by first segmenting the images and then normalizing the gray matter images to the customized gray matter template. The normalization parameters were then applied to the original whole head. The images were then segmented using customized prior probability maps, modulated, and smoothed with an 8-mm fullwidth at half-maximum smoothing kernel.
A single-subject condition and covariate model was used to compare the smoothed modulated gray matter images between the groups of AD subjects with and without abTDP-43 immunoreactivity and controls at a statistical threshold of p Ͻ 0.05 corrected for multiple comparisons using the family-wise error (FWE). Age and sex were included as nuisance variables. Direct comparisons between the AD subjects with and without immunoreactivity were performed correcting for multiple comparisons using the false discovery rate (FDR) 30 at p Ͻ 0.05 because of the hypothesis-driven nature of these statistical tests. In addition, direct comparisons were performed between the abTDP-43 immunoreactive subjects with and without Hp-Scl, as well as between the different histologic types (0, 1, and 3).
Statistical methods. Statistical analyses were performed
using JMP computer software (JMP Software, version 6.0.0; SAS Institute Inc., Cary, NC) with ␣ set at 0.05. All binary data were compared across groups with the 2 test. A pooled t test was used to compare continuous data across both groups. Consortium to Establish a Registry for Alzheimer's Disease (CERAD) and NIA-Reagan data were converted into an ordinal scale for the purposes of statistical analysis (CERAD: 0 ϭ O, 1 ϭ A, 2 ϭ B, and 3 ϭ C; NIA-Reagan: 0 ϭ low probability of AD, 1 ϭ intermediate probability, and 2 ϭ high probability). Logistic regression was used to assess the relationship of disease severity measures (CDR-SB and MMSE scores) adjusted for age at testing, with the presence of abTDP-43 immunoreactivity. Similar analysis was conducted for pathologic variables adjusted for age at death. A multivariate logistic regression model was built by including age at death and adding any pathologic variable that was significant (p Յ 0.1) with univariate analysis to determine which model best predicted abTDP-43 immunoreactivity. Because each of the primary associations evaluated in this study was of interest in its own right and not data driven, we did not adjust for multiple comparisons. 31, 32 In a secondary analysis assessing associations across histologic Types 0, 1, and 3, the 2 test was used to analyze nominal data, whereas analysis of variance was used for continuous data or ordinal data treated as continuous.
RESULTS
Of the 84 subjects with intermediateto high-probability AD pathology, 29 subjects (34%) had evidence of abTDP-43 immunoreactivity (table 1). All 29 subjects received a clinical diagnosis of Alzheimer-type dementia before death, and in none was a clinical diagnosis of any of the frontotemporal dementia variants or motor neuron disease made. Those with abTDP-43 immunoreactivity were older at onset and at death. After adjusting for age at death, those with abTDP-43 immunoreactivity had clinically more severe dementia with worse CDR-SB (p ϭ 0.03) and MMSE scores (p ϭ 0.01) than those without abTDP-43 immunoreactivity. The MMSE scores at dementia onset were also worse in those with abTDP-43 immunoreactivity compared with those without (p ϭ 0.03).
Neuropsychometrics. Neuropsychometric results are shown in table 2. By using MOANS scores, [19] [20] [21] which adjust for age, as well as adjusting for education, those with abTDP-43 immunoreactivity performed worse on the Boston Naming Test 15 (p ϭ 0.04) than those without abTDP-43 immunoreactivity. There was no difference between the groups on any other neuropsychometric score, or from time of disease onset to time at testing. Apolipoprotein E genotyping. There was no difference in apolipoprotein E4 allele frequency between those with and without abTDP-43 immunoreactivity (table 1).
Pathology. After adjusting for age at death, HpScl (p ϭ 0.008) and the presence of LBs (p ϭ 0.04) were more frequent in the group of subjects with abTDP-43 immunoreactivity compared with those without any immunoreactivity (p ϭ 0.008), and those with abTDP-43 immunoreactivity had lower brain weights at death (p ϭ 0.04) (table 1).
In the multivariate analysis, only HpScl (p ϭ 0.02), not the presence of LBs (p ϭ 0.19), predicted TDP-43 immunoreactivity. There was no difference in age at death or CDR-SB or MMSE scores between subjects with abTDP-43 immunoreactivity with and without HpScl.
Using the classification scheme of Mackenzie et al. 7 for FTLD-U, 7 of the 29 cases with abTDP-43 immunoreactivity were classified as Type 1, 1 case was classified as Type 2, and 16 cases were classified as Type 3 (figure 1). Five cases had sparse abTDP-43 immunoreactivity and could not be classified and were considered to have Type 0. Demographic, clinical, and pathologic variables were similar across all types (table e-1 on the Neurology ® Web site at www.neurology.org). For neuropsychological variables, only the Boston Naming Test scores were different across the three types (p ϭ 0.03). The Boston Naming Test score was highest in Type 0 (mean 6.8 [SD 1.3]), followed by Type 1 (mean 4 [SD 2.9]) and then Type 3 (mean 3.2 [SD 2.0]). Most of the abTDP-43 immunoreactivity in Type 0 was associated with NFT in the subiculum or entorhinal cortex. They did not have abTDP-43 immunoreac- tive neurites or NII. Only one of the 5 cases had sparse inclusions in the dentate granule cell layer of the hippocampus. Ten (34%) of the 29 cases with abTDP-43 immunoreactivity had NII. Neuronal intranuclear inclusions were most frequent in Type 1 (p ϭ 0.03) compared with other types.
Genetics. Of those subjects with NII, seven were screened, and all seven were negative for any mutation in the progranulin gene.
Imaging. There was a trend for those with abTDP-43 immunoreactivity to be slightly older at the time of scan than those without abTDP-43 immunoreactivity, although there was no difference between the groups in time from disease onset to scan or time from scan to death (table 1) . Voxelbased morphometry adjusting for age at scan showed a similar pattern of gray matter loss in those with and without abTDP-43 immunoreactivity compared with controls ( figure 2, A and B) . Both groups showed a pattern of gray matter loss predominantly involving medial temporal lobes and temporoparietal neocortex when compared with controls (p Ͻ 0.05, corrected for multiple comparisons using the FWE). When directly compared ( figure 2C) , however, those with abTDP-43 immunoreactivity showed evidence of greater volume loss in the medial temporal lobe, particularly the hippocampus, than those without abTDP-43 immunoreactivity (p Ͻ 0.05, corrected for multiple comparisons using the FDR). Although the subjects without abTDP-43 immunoreactivity seemed to show a more widespread pattern of cortical loss than those with abTDP-43 immunoreactivity, on direct comparison no regions showed greater gray matter loss in the group without abTDP-43 immunoreactivity. Because HpScl was identified as being a predictor of abTDP-43 immunoreactivity on multivariate analysis, we also performed a secondary analysis comparing the subjects with abTDP-43 immunoreactivity with and without HpScl. No differences were identified between these groups (uncorrected, p Ͻ 0.001). In addition, no differences were identified between Histologic characteristics of FTLD-U types 1,2, and 3
Abnormal TAR DNA-binding protein 43 immunoreactivity in AD was classified into one of three histologic types according to the scheme proposed by Mackenzie et al. 7 with medial temporal cortex (A-C) and dentate fascia of the hippocampus (D-F). Type 1 had neuronal cytoplasmic inclusions and short neurites in the cortex (A) and granular cytoplasmic inclusions in the dentate fascia (D). Some cases had intranuclear inclusions (inset). Type 2 had neurites but few or no cytoplasmic inclusions in the cortex (B) and characteristic long, tapering neurites (inset); round, Pick body-like inclusions were noted in the dentate fascia (E). Type 3 had cytoplasmic inclusions with few neurites in the cortex (C) and variable dentate fascia inclusions (F). histologic Types 0, 1, and 3 (uncorrected, p Ͻ 0.001).
DISCUSSION
In this study, we found that 34% of AD subjects had abTDP-43 immunoreactivity in medial temporal lobe structures. There were a number of clinical, neuropsychological, imaging, and pathologic differences between those with and without abTDP-43 immunoreactivity, suggesting that the presence of abTDP-43 immunoreactivity in AD may be associated with a modified phenotype. Abnormal TDP-43 has been identified as one of the major disease proteins in FTLD-U and has been suggested to be specific to neuronal inclusions and neurites in FTLD-U and sporadic ALS. 2 Recent studies, however, have shown abTDP-43 immunoreactivity in AD, 6 Parkinson dementia complex of Guam, 33 and LB disease. 34 The current study and another 6 showed that 23% to 34% of AD subjects have some abTDP-43 immunoreactivity. Those with abTDP-43 immunoreactivity scored worse on the CDR-SB closest to death and MMSE at dementia onset and closest to death, as well as on a neuropsychological test of confrontation naming. In addition, they had more hippocampal atrophy on MRI and more frequent HpScl at autopsy. These results were not driven by longer disease durations or older age. It seems biologically plausible that in those with abTDP-43 immunoreactivity the presence of HpScl might be driving the worse hippocampal atrophy 35 ; however, within the group of subjects with abTDP-43 immunoreactivity, there was no difference in hippocampal volume loss in those with and without HpScl. This suggests that abTDP-43 immunoreactivity, independent of HpScl, is associated with hippocampal atrophy.
The overall pattern of volume loss observed in the affected groups compared to controls was typical of volume loss observed in AD, suggesting that AD pathology is the main driving force of the overall patterns of atrophy. On direct comparison of affected groups, however, we observed more hippocampal atrophy in those with abTDP-43 immunoreactivity. Severe hippocampal atrophy has been observed in certain variants of frontotemporal dementia, such as semantic dementia and behavioral variant frontotemporal dementia. 36 Therefore, the question arises as to whether the presence of abTDP-43 immunoreactivity signifies the presence of an underlying frontotemporal dementia. Unfortunately, we are unable to determine exactly how much atrophy is driven purely by the presence of abTDP-43 immunoreactivity and how much is driven purely by HpScl.
Figure 2
Results of voxel-based morphometry showing similarity in the patterns of gray matter atrophy in both groups of subjects with and without abTDP-43 immunoreactivity on a threedimensional render Subjects with abTDP-43 immunoreactivity were cognitively more impaired at the time of first and last clinical evaluation. Whereas the MMSE was different at dementia onset and closest to death, the CDR-SB was not different at dementia onset, only closest to death. This suggests that the difference in cognitive measures between subjects with and without abTDP-43 is amplified with disease progression, although findings just before death are more difficult to interpret. These differences were also unlikely to be driven by the higher frequency of HpScl in those with abTDP-43 immunoreactivity, because there were no differences in CDR-SB or MMSE between those with and without HpScl. Subjects with abTDP-43 immunoreactivity showed greater deficits in confrontation naming as measured by the Boston Naming Test. This is not surprising, because studies have implicated the hippocampus to play a role in poor performance on the Boston Naming Test. 37 We did not find any difference, however, on the Trail Making B and Controlled Word Association Tests, in keeping with absence of any difference in volume loss in the frontal lobes assessed on VBM, because these two neuropsychological tests are associated mainly with frontal lobe impairment. 38, 39 There was also no difference on tests of memory, which is not surprising, because both groups with and without abTDP-43 immunoreactivity had high-probability AD. 8 A limitation to the neuropsychological battery completed in these subjects was the limited number of executive test performed.
It could be hypothesized that the presence of abTDP-43 immunoreactivity in subjects with AD represents concomitant AD and FTLD-U. 6 The high frequency of HpScl in the abTDP-43 immunoreactive group supports this hypothesis because HpScl is highly associated with FTLD-U. 35, 40 The fact that those with abTDP-43 immunoreactivity were cognitively and functionally worse than those without immunoreactivity could be caused by the combined effects of AD and FTLD-U. The average age at onset of subjects with FTLD-U pathology has been reported to be less than 65 years, and although the average age at onset of our subjects with abTDP-43 immunoreactivity was greater than 65 years, the average age is within the range reported for FTLD-U. 4 Subjects with FTLD-U pathology have a striking pattern of frontotemporal volume loss on MRI. It is therefore possible that the AD pathology may have masked that pattern, especially if the AD pathology occurred before the FTLD-U pathology. The fact that those with abTDP-43 immunoreac-tivity also had lower brain weights at autopsy would also support this hypothesis of dual pathologies, as well as a hypothesis of more aggressive disease in those with abTDP-43 immunoreactivity.
Several classification schemes have been proposed for FTLD-U, and one has been reported to show correlation with clinical phenotypes. 7 When the latter classification was applied to AD, the majority of the cases had abTDP-43 immunoreactivity consistent with Type 3. It has been suggested that this type is associated with behavioral variant frontotemporal dementia and sometimes motor neuron disease. 7 None of our subjects with abTDP-43 immunoreactivity had motor neuron disease or a clinical diagnosis of frontotemporal dementia. Moreover, we did not find any significant differences between the three types. The lack of differences across the types in AD, unlike in FTLD-U, may not have meaningful significance, possibly because the AD pathology may mask the features of FTLD-U. In addition, NII have been reported to be characteristic of FTLD linked to progranulin mutations. 26 However, all of our AD cases with abTDP-43 immunoreactivity and NII screened for progranulin mutations were negative.
The significance of increased LBs in AD with abTDP-43 immunoreactivity is unclear. However, abTDP-43 immunoreactivity has been observed in subjects with LBs. 26, 34 It is unlikely that the presence of LBs played a role in worse hippocampal atrophy in the abTDP-43 immunoreactive group, because VBM analysis of subjects with LB disease show, on average, less hippocampal volume loss than in AD. 28 
